Anthony Monzon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anthony Monzon has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Omar Samara
Department of Orthopedic Surgery, Rutgers New Jersey Medical School, Newark, New Jersey
2 shared publications - Andres Felipe Henao-Martinez
Division of Infectious Diseases, University of Colorado , Aurora, Colorado
1 shared publication - Anis Rassi
Department of Cardiology, Hospital do Coração Anis Rassi, Goiânia, Brazil
1 shared publication - Brian William Herrmann
Department of Otolaryngology, University of Colorado School of Medicine, Aurora, CO, USA; Department of Pediatric Otolaryngology, Children's Hospital Colorado, Aurora, CO, USA
1 shared publication - Carlos Franco-Paredes
Hospital Infantil de México, Ciudad de México, Mexico
1 shared publication - Deepika Gudapati
NRI Medical College , Guntur, Andhra Pradesh
1 shared publication
Latest Publications
- 7 June 2023
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 44 (5) , 103948
Pediatric primary salivary gland tumors
- 7 June 2023
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 44 (5) , 103948
Pediatric primary salivary gland tumors
- Open Access
- 30 October 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (6) , 5466-5481
Mortality Risk in Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis
Aims This study aimed to estimate the annual mortality risk and its determinants in chronic Chagas cardiomyopathy. Methods and results We conducted a systematic search in MEDLINE, Web of Science Core Collection, Embase, Cochrane Library, and LILACS. Longitudinal studies published between 1 January 1946 and 24 October 2018 were included. A random-effects meta-analysis using the death rate over the mean follow-up period in years was used to obtain pooled estimated annual mortality rates. Main outcomes were defined as all-cause mortality, including cardiovascular, non-cardiovascular, heart failure, stroke, and sudden cardiac deaths. A total of 5005 studies were screened for eligibility. A total of 52 longitudinal studies for chronic Chagas cardiomyopathy including 9569 patients and 2250 deaths were selected. The meta-analysis revealed an annual all-cause mortality rate of 7.9% [95% confidence interval (CI): 6.3–10.1; I2 = 97.74%; T2 = 0.70] among patients with chronic Chagas cardiomyopathy. The pooled estimated annual cardiovascular death rate was 6.3% (95% CI: 4.9–8.0; I2 = 96.32%; T2 = 0.52). The annual mortality rates for heart failure, sudden death, and stroke were 3.5%, 2.6%, and 0.4%, respectively. Meta-regression showed that low left ventricular ejection fraction (coefficient = −0.04; 95% CI: −0.07, −0.02; P = 0.001) was associated with an increased mortality risk. Subgroup analysis based on American Heart Association (AHA) classification revealed pooled estimate rates of 4.8%, 8.7%, 13.9%, and 22.4% (P < 0.001) for B1/B2, B2/C, C, and C/D stages of cardiomyopathy, respectively. Conclusions The annual mortality risk in chronic Chagas cardiomyopathy is substantial and primarily attributable to cardiovascular causes. This risk significantly increases in patients with low left ventricular ejection fraction and those classified as AHA stages C and C/D.
- 30 October 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (6) , 5466-5481
Open AccessMortality Risk in Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis
Aims This study aimed to estimate the annual mortality risk and its determinants in chronic Chagas cardiomyopathy. Methods and results We conducted a systematic search in MEDLINE, Web of Science Core Collection, Embase, Cochrane Library, and LILACS. Longitudinal studies published between 1 January 1946 and 24 October 2018 were included. A random-effects meta-analysis using the death rate over the mean follow-up period in years was used to obtain pooled estimated annual mortality rates. Main outcomes were defined as all-cause mortality, including cardiovascular, non-cardiovascular, heart failure, stroke, and sudden cardiac deaths. A total of 5005 studies were screened for eligibility. A total of 52 longitudinal studies for chronic Chagas cardiomyopathy including 9569 patients and 2250 deaths were selected. The meta-analysis revealed an annual all-cause mortality rate of 7.9% [95% confidence interval (CI): 6.3–10.1; I2 = 97.74%; T2 = 0.70] among patients with chronic Chagas cardiomyopathy. The pooled estimated annual cardiovascular death rate was 6.3% (95% CI: 4.9–8.0; I2 = 96.32%; T2 = 0.52). The annual mortality rates for heart failure, sudden death, and stroke were 3.5%, 2.6%, and 0.4%, respectively. Meta-regression showed that low left ventricular ejection fraction (coefficient = −0.04; 95% CI: −0.07, −0.02; P = 0.001) was associated with an increased mortality risk. Subgroup analysis based on American Heart Association (AHA) classification revealed pooled estimate rates of 4.8%, 8.7%, 13.9%, and 22.4% (P < 0.001) for B1/B2, B2/C, C, and C/D stages of cardiomyopathy, respectively. Conclusions The annual mortality risk in chronic Chagas cardiomyopathy is substantial and primarily attributable to cardiovascular causes. This risk significantly increases in patients with low left ventricular ejection fraction and those classified as AHA stages C and C/D.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 8
Cartoons and the internet: preparing the physicians of tomorrow
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 8
Open AccessCartoons and the internet: preparing the physicians of tomorrow